STOCK TITAN
  1. Home
  2. Sec-filings
  3. INTS
  4. [8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock INTS logo
INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

#8304 Ranked by Market Cap
N/A Ranked by Dividends

INTS Latest News

Jun 30, 2025
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
Jun 11, 2025
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
Jun 11, 2025
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Jun 11, 2025
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
May 29, 2025
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

INTS Latest SEC Filings

Jul 9, 2025
[SCHEDULE 13G/A] Intensity Therapeutics, Inc. Common stock SEC Filing
Jul 2, 2025
[Form 4] Intensity Therapeutics, Inc. Common stock Insider Trading Activity
Jul 2, 2025
[Form 4] Intensity Therapeutics, Inc. Common stock Insider Trading Activity
Jun 27, 2025
[S-8] Intensity Therapeutics, Inc. Common stock Employee Benefit Plan Registration

INTS Stock Data

8.25M
18.84M
42.78%
17.92%
0.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SHELTON